Bal Pharma Ltd

Bal Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 17 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 September 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Bal Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 17 Aug 2026. This decision follows a comprehensive reassessment across four key parameters: quality, valuation, financial trend, and technicals. Despite a very attractive valuation, concerns over flat financial performance, weak long-term fundamentals, and mixed technical signals have weighed heavily on the stock’s outlook.

Bal Pharma Ltd has seen a marked improvement in its valuation parameters, shifting from an attractive to a very attractive rating, despite a recent dip in share price and ongoing sector headwinds. This development comes as the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now present a compelling case for investors seeking value within the Pharmaceuticals & Biotechnology sector.

Bal Pharma Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical indicators and valuation metrics despite ongoing challenges in its financial trend and long-term fundamentals. The upgrade, effective from 12 August 2026, is driven primarily by a bullish shift in technicals and an attractive valuation relative to peers, while the company’s quality and financial trend parameters remain subdued.

Bal Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 6 August 2026. This change reflects a combination of deteriorating technical indicators, flat financial performance, and weak long-term fundamentals, despite some attractive valuation metrics. The company’s stock price has also underperformed key benchmarks, signalling caution for investors.

Bal Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 14 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Bal Pharma Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 14 July 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 26 July 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.

Bal Pharma Ltd has seen a significant shift in its valuation parameters, moving from an attractive to a very attractive rating, despite a modest decline in its share price. This change reflects improving price-to-earnings and price-to-book value ratios relative to its historical averages and peer group, signalling a potential opportunity for investors in the Pharmaceuticals & Biotechnology sector.

Bal Pharma Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical indicators and valuation metrics despite ongoing challenges in financial performance and long-term growth. The upgrade, effective from 14 Jul 2026, is driven primarily by bullish technical trends and a more attractive valuation profile relative to its pharmaceutical peers.

Bal Pharma Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, reflecting improved price appeal relative to its historical averages and peer group. This upgrade comes amid a volatile pharmaceutical sector landscape, where the company’s micro-cap status and recent price surge have drawn investor attention despite mixed longer-term returns.

Bal Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 July 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.

Bal Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from an attractive to a very attractive rating. Despite recent share price declines and a challenging market environment, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a compelling entry point relative to its peers and historical averages.

Bal Pharma Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 08 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Bal Pharma Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has been downgraded from a Strong Sell to a Sell rating following a comprehensive review of its financial performance, valuation metrics, and technical indicators. Despite some attractive valuation aspects, the company’s flat quarterly results, weak long-term fundamentals, and deteriorating financial trends have prompted a cautious stance from analysts.